1:37 PM
 | 
Feb 14, 2018
 |  BC Extra  |  Company News

J&J scores two firsts for Erleada approval

FDA approved an NDA for Erleada apalutamide (JNJ56021927) from Johnson & Johnson (NYSE:JNJ) to treat non-metastatic castration-resistant prostate cancer (CRPC), making it the first approved drug for the indication and the first approval based on a metastatic-free survival (MFS) primary endpoint,...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >